Delivery Order SPE2DB20D1109-SPE2DB25FP42D
- Not listed
- The Defense Logistics Agency awarded a $35,153.85 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. The contract, which is non-set-aside and competitively awarded, carries an ultimate completion date of September 3, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, valued at $2,343.59 with a firm fixed price structure. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 through December 2026. The award carries no set-aside designation and was competitively...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $2,343.59 on August 18, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 9, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a $14,061.54 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. The contract, which is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), carries an ultimate completion date of September 3, 2025, and involves no set-aside designation....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, valued at $2,469.78. This is a firm fixed-price delivery order with no set-aside designation, to be completed by December 9, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $2,343.59 delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, with an ultimate completion date of July 11, 2025. This firm fixed-price, non-set-aside contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors with an ultimate completion date of September 11, 2025. This competitive award was issued under a firm fixed-price contract structure with no set-aside designation. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $2,469.78 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen injectors on November 20, 2025, with completion expected by December 12, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Tezspire is a specialty biologic medication used in the treatment of severe asthma,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for Tezspire 210 mg/1.91 mL pen injectors valued at $2,343.59 with a firm fixed price contract type. The order is scheduled for completion by September 29, 2025, with performance at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This is a non-set-aside competitive award issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $2,469.78 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen injectors, with an ultimate completion date of January 13, 2026. This is a firm fixed price, non-set-aside contract with performance at the vendor's Conshohocken, Pennsylvania location. The award represents a single delivery order under a larger indefinite delivery contract vehicle. This delivery order falls under AmerisourceBergen Drug Corp's $999,999,999.00...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP42DDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, with an ultimate completion date of August 8, 2025. This is a firm fixed-price contract with no set-aside designation, performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a competitive award to the pharmaceutical distributor, which serves as a critical vendor for federal medical procurement supporting military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This prime contract vehicle provides comprehensive global pharmaceutical support, enabling the company to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide, including customers such as the Defense Health Agency and the U.S. Coast Guard. Tezspire is a specialty biologic medication used for severe asthma treatment, reflecting the company's role in delivering specialized pharmaceutical products across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 7/18/25 |